肝癌局部治疗——消融或切除?

史瑶平; 翟博

doi:10.3969/j.issn.1001-5256.2021.03.003

肝癌局部治疗——消融或切除?

DOI: 10.3969/j.issn.1001-5256.2021.03.003

史瑶平,
翟博^,

上海交通大学医学院附属仁济医院肿瘤介入科，上海 200127

基金项目:

国家自然科学基金 (81801800)

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：史瑶平负责调研整理文献及起草论文；翟博负责提出文章选题、设计论文框架及修订论文。

详细信息

作者简介:
史瑶平(1983—)，男，主治医师，博士，主要研究肝癌的综合介入及靶向免疫治疗

通信作者:
翟博，zhaiboshi@sina.com

中图分类号: R735.7
计量
- 文章访问数: 432
- HTML全文浏览量: 220
- PDF下载量: 81
- 被引次数: 0
出版历程
- 收稿日期: 2021-02-18
- 录用日期: 2021-02-18
- 出版日期: 2021-03-20

Local treatment of liver cancer: Ablation or resection?

Yaoping SHI,
Bo ZHAI^,

Department of Interventional Radiology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200127, China

摘要

摘要: 肝癌是我国常见的恶性肿瘤之一，手术切除目前仍然是肝癌患者首选的根治性方法，但大部分患者由于受肿瘤大小及部位、肝功能和整体状况的影响，不能耐受手术切除。近年来，以射频和微波为代表的局部消融技术迅速发展，并在临床中广泛应用，更被誉为堪与外科切除相媲美的肝癌根治性治疗的新技术。就局部消融与外科切除在肝癌治疗中的应用和选择作一简介。
- 肝肿瘤 /
- 消融技术 /
- 肝切除术
Abstract: Liver cancer is one of the most common malignant tumors in China. Surgical resection is still the preferred radical treatment method for patients with liver cancer; however, most patients cannot tolerate surgical resection due to the influence of tumor size, tumor location, liver function, and general condition. In recent years, local ablation techniques, such as radiofrequency ablation and microwave ablation, have developed rapidly and are widely used in clinical practice, and they are even known as new techniques comparable to surgical resection for the radical treatment of liver cancer. This article briefly introduces the application and selection of local ablation and surgical resection in the treatment of liver cancer.
- Liver Neoplasms /
- Ablation Techniques /
- Hepatectomy

HTML全文

参考文献(44)

[1]	GEYIK S, AKHAN O, ABBASOGLU O, et al. Radiofrequency ablation of unresectable hepatic tumors[J]. Diagn Interv Radiol, 2006, 12(4): 195-200. http://www.ncbi.nlm.nih.gov/pubmed/11503676
[2]	POGGI G, TOSORATTI N, MONTAGNA B, et al. Microwave ablation of hepatocellular carcinoma[J]. World J Hepatol, 2015, 7(25): 2578-2589. DOI: 10.4254/wjh.v7.i25.2578
[3]	THANOS, L, POULOU LS, ZIAKAS PD, et al. Image-guided radiofrequency ablation (RFA) of unresectable hepatic tumors using a triple-spiral-shaped electrode needle: Initial experience in 34 patients[J]. Cardiovasc Intervent Radiol, 2010, 33(1): 107-112. DOI: 10.1007/s00270-009-9649-9
[4]	VIBERT E, SCHWARTZ M, OLTHOFF KM. Advances in resection and transplantation for hepatocellular carcinoma[J]. J Hepatol, 2020, 72(2): 262-276. DOI: 10.1016/j.jhep.2019.11.017
[5]	PINNA AD, YANG T, MAZZAFERRO V, et al. Liver transplantation and hepatic resection can achieve cure for hepatocellular carcinoma[J]. Ann Surg, 2018, 268(5): 868-875. DOI: 10.1097/SLA.0000000000002889
[6]	CHACKO S, SAMANTA S. Hepatocellular carcinoma: A life-threatening disease[J]. Biomed Pharmacother, 2016, 84: 1679-1688. DOI: 10.1016/j.biopha.2016.10.078
[7]	OGATA S, BELGHITI J, FARGES O, et al. Sequential arterial and portal vein embolizations before right hepatectomy in patients with cirrhosis and hepatocellular carcinoma[J]. Br J Surg, 2006, 93(9): 1091-1098. DOI: 10.1002/bjs.5341
[8]	ISHIZAWA T, HASEGAWA K, AOKI T, et al. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma[J]. Gastroenterology, 2008, 134(7): 1908-1916. DOI: 10.1053/j.gastro.2008.02.091
[9]	FUKS D, DOKMAK S, PARADIS V, et al. Benefit of initial resection of hepatocellular carcinoma followed by transplantation in case of recurrence: An intention-to-treat analysis[J]. Hepatology, 2012, 55(1): 132-140. DOI: 10.1002/hep.24680
[10]	BRUIX J, SHERMAN M, Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma[J]. Hepatology, 2005, 42(5): 1208-1236. DOI: 10.1002/hep.20933
[11]	HUANG J, YAN L, CHENG Z, et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria[J]. Ann Surg, 2010, 252(6): 903-912. DOI: 10.1097/SLA.0b013e3181efc656
[12]	BREEN DJ, LENCIONI R. Image-guided ablation of primary liver and renal tumours[J]. Nat Rev Clin Oncol, 2015, 12(3): 175-186. DOI: 10.1038/nrclinonc.2014.237
[13]	AHMED M, BRACE CL, LEE FT Jr, et al. Principles of and advances in percutaneous ablation[J]. Radiology, 2011, 258(2): 351-369. DOI: 10.1148/radiol.10081634
[14]	YU NC, RAMAN SS, KIM YJ, et al. Microwave liver ablation: Influence of hepatic vein size on heat-sink effect in a porcine model[J]. J Vasc Interv Radiol, 2008, 19(7): 1087-1092. DOI: 10.1016/j.jvir.2008.03.023
[15]	SCHRAMM W, YANG D, WOOD BJ, et al. Contribution of direct heating, thermal conduction and perfusion during radiofrequency and microwave ablation[J]. Open Biomed Eng J, 2007, 1: 47-52. DOI: 10.2174/1874120700701010047
[16]	SHIBATA T, ⅡMURO Y, YAMAMOTO Y, et al. Small hepatocellular carcinoma: Comparison of radio-frequency ablation and percutaneous microwave coagulation therapy[J]. Radiology, 2002, 223(2): 331-337. DOI: 10.1148/radiol.2232010775
[17]	LU MD, XU HX, XIE XY, et al. Percutaneous microwave and radiofrequency ablation for hepatocellular carcinoma: A retrospective comparative study[J]. J Gastroenterol, 2005, 40(11): 1054-1060. DOI: 10.1007/s00535-005-1671-3
[18]	QIAN GJ, WANG N, SHEN Q, et al. Efficacy of microwave versus radiofrequency ablation for treatment of small hepatocellular carcinoma: Experimental and clinical studies[J]. Eur Radiol, 2012, 22(9): 1983-1990. DOI: 10.1007/s00330-012-2442-1
[19]	YU J, YU XL, HAN ZY, et al. Percutaneous cooled-probe microwave versus radiofrequency ablation in early-stage hepatocellular carcinoma: A phase Ⅲ randomised controlled trial[J]. Gut, 2017, 66(6): 1172-1173. DOI: 10.1136/gutjnl-2016-312629
[20]	LIU Y, ZHENG Y, LI S, et al. Percutaneous microwave ablation of larger hepatocellular carcinoma[J]. Clin Radiol, 2013, 68(1): 21-26. DOI: 10.1016/j.crad.2012.05.007
[21]	XU LF, SUN HL, CHEN YT, et al. Large primary hepatocellular carcinoma: Transarterial chemoembolization monotherapy versus combined transarterial chemoembolization-percutaneous microwave coagulation therapy[J]. J Gastroenterol Hepatol, 2013, 28(3): 456-463. DOI: 10.1111/jgh.12088
[22]	ABDELAZIZ AO, NABEEL MM, ELBAZ TM, et al. Microwave ablation versus transarterial chemoembolization in large hepatocellular carcinoma: Prospective analysis[J]. Scand J Gastroenterol, 2015, 50(4): 479-484. DOI: 10.3109/00365521.2014.1003397
[23]	COPPER IS. Cryogenic surgery: A new method of destruction or extirpation of benign or malignant tissues[J]. N Engl J Med, 1963, 268: 743-749. DOI: 10.1056/NEJM196304042681401
[24]	JUNGRAITHMAYR W, BURGER D, OLSCHEWSKI M, et al. Cryoablation of malignant liver tumors: Results of a single center study[J]. Hepatobiliary Pancreat Dis Int, 2005, 4(4): 554-560. http://qikan.cqvip.com/Qikan/Article/Detail?id=1003033805
[25]	SEIFERT JK, MORRIS DL. World survey on the complications of hepatic and prostate cryotherapy[J]. World J Surg, 1999, 23(2): 109-113; discussion 113-114.
[26]	SMITH MT, RAY CE. The treatment of primary and metastatic hepatic neoplasms using percutaneous cryotherapy[J]. Semin Intervent Radiol, 2006, 23(1): 39-46. DOI: 10.1055/s-2006-939840
[27]	BILCHIK AJ, WOOD TF, ALLEGRA D, et al. Cryosurgical ablation and radiofrequency ablation for unresectable hepatic malignant neoplasms: A proposed algorithm[J]. Arch Surg, 2000, 135(6): 657-662; discussion 662-664.
[28]	GOLDBERG SN, GRASSI CJ, CARDELLA JF, et al. Image-guided tumor ablation: Standardization of terminology and reporting criteria[J]. J Vasc Interv Radiol, 2009, 20(7 Suppl): s377-s390. http://www.sciencedirect.com/science/article/pii/s1051044314008458
[29]	PACELLA CM, BIZZARRI G, FRANCICA G, et al. Analysis of factors predicting survival in patients with hepatocellular carcinoma treated with percutaneous laser ablation[J]. J Hepatol, 2006, 44(5): 902-909. DOI: 10.1016/j.jhep.2006.01.031
[30]	FRANCICA G, PETROLATI A, di STASIO E, et al. Effectiveness, safety, and local progression after percutaneous laser ablation for hepatocellular carcinoma nodules up to 4 cm are not affected by tumor location[J]. AJR Am J Roentgenol, 2012, 199(6): 1393-1401. DOI: 10.2214/AJR.11.7850
[31]	PACELLA CM, BIZZARRI G, FRANCICA G, et al. Percutaneous laser ablation in the treatment of hepatocellular carcinoma with small tumors: Analysis of factors affecting the achievement of tumor necrosis[J]. J Vasc Interv Radiol, 2005, 16(11): 1447-1457. DOI: 10.1097/01.RVI.90000172121.82299.38
[32]	POMPILI M, PACELLA CM, FRANCICA G, et al. Percutaneous laser ablation of hepatocellular carcinoma in patients with liver cirrhosis awaiting liver transplantation[J]. Eur J Radiol, 2010, 74(3): e6-e11. DOI: 10.1016/j.ejrad.2009.03.012
[33]	LENCIONI R, CIONI D, DELLA PINA C, et al. Hepatocellular carcinoma: New options for image-guided ablation[J]. J Hepatobiliary Pancreat Sci, 2010, 17(4): 399-403. DOI: 10.1007/s00534-009-0233-0
[34]	NARAYANAN G. Irreversible electroporation for treatment of liver cancer[J]. Gastroenterol Hepatol (N Y), 2011, 7(5): 313-316. http://www.ncbi.nlm.nih.gov/pubmed/21857833
[35]	MAOR E, IVORRA A, LEOR J, et al. The effect of irreversible electroporation on blood vessels[J]. Technol Cancer Res Treat, 2007, 6(4): 307-312. DOI: 10.1177/153303460700600407
[36]	CHARPENTIER KP, WOLF F, NOBLE L, et al. Irreversible electroporation of the liver and liver hilum in swine[J]. HPB (Oxford), 2011, 13(3): 168-173. DOI: 10.1111/j.1477-2574.2010.00261.x
[37]	Bureau of Medical Administration, National Health Commission of the People's Republic of China. Guidelines for diagnosis and treatment of primary liver cancer in China (2019 edition)[J]. J Clin Hepatol, 2020, 36(2): 277-292. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2020.05.009 中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 临床肝胆病杂志, 2020, 36(2): 277-292. DOI: 10.3969/j.issn.1001-5256.2020.05.009
[38]	CHEN MS, LI JQ, ZHENG Y, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma[J]. Ann Surg, 2006, 243(3): 321-328. DOI: 10.1097/01.sla.0000201480.65519.b8
[39]	FANG Y, CHEN W, LIANG X, et al. Comparison of long-term effectiveness and complications of radiofrequency ablation with hepatectomy for small hepatocellular carcinoma[J]. J Gastroenterol Hepatol, 2014, 29(1): 193-200. DOI: 10.1111/jgh.12441
[40]	NG K, CHOK K, CHAN A, et al. Randomized clinical trial of hepatic resection versus radiofrequency ablation for early-stage hepatocellular carcinoma[J]. Br J Surg, 2017, 104(13): 1775-1784. DOI: 10.1002/bjs.10677
[41]	LAU WY, LAI EC. The current role of radiofrequency ablation in the management of hepatocellular carcinoma: A systematic review[J]. Ann Surg, 2009, 249(1): 20-25. DOI: 10.1097/SLA.0b013e31818eec29
[42]	PENG ZW, ZHANG YJ, CHEN MS, et al. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: A prospective randomized trial[J]. J Clin Oncol, 2013, 31(4): 426-432. DOI: 10.1200/JCO.2012.42.9936
[43]	MORIMOTO M, NUMATA K, KONDOU M, et al. Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma: A randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization[J]. Cancer, 2010, 116(23): 5452-5460. DOI: 10.1002/cncr.25314
[44]	KAGAWA T, KOIZUMI J, KOJIMA S, et al. Transcatheter arterial chemoembolization plus radiofrequency ablation therapy for early stage hepatocellular carcinoma: Comparison with surgical resection[J]. Cancer, 2010, 116(15): 3638-3644. DOI: 10.1002/cncr.25142